900-day follow-up highlights PAE’s promise in canine prostate cancer
Bottom line
A new Frontiers in Veterinary Science case report describes what may be the longest published imaging follow-up after prostatic artery embolization, or PAE, in a dog with prostatic carcinoma: about 900 days of CT, ultrasound, and thoracic imaging after treatment. The patient, a 13-year-old neutered male Chihuahua, had sustained local disease control after the minimally invasive procedure, with clinical signs reportedly well managed and survival to Day 918. The authors reported intraprostatic ischemic and cavitary changes on CT and chronic remodeling changes on ultrasound, along with an approximately 33% drop in prostatic parenchymal volume that remained stable until Day 481, and no serious PAE-related complications. (frontiersin.org)
Why it matters: Canine prostatic carcinoma remains a difficult disease to manage, with no established curative treatment and a high rate of metastasis at diagnosis. That makes durable local control and symptom relief clinically meaningful, especially for patients that may not be candidates for surgery or radiation. PAE is still supported mainly by small studies and case series, but prior work has shown short-term feasibility, and UC Davis has described embolization as a major local therapy in its prostate cancer caseload. For general practitioners and specialists, this report adds unusually long imaging follow-up to a growing body of evidence that interventional oncology may offer a practical palliative option for selected dogs. (merckvetmanual.com)
What to watch: Whether larger prospective studies can show which dogs benefit most from PAE, how often it meaningfully extends quality survival, and how it compares with NSAIDs, radiation, and multimodal care. (pubmed.ncbi.nlm.nih.gov)
Key facts
- Study type
- Case report
- Journal
- Frontiers in Veterinary Science
- Patient
- 13-year-old neutered male Chihuahua
- Condition
- Prostatic carcinoma
- Procedure
- Prostatic artery embolization (PAE)
- Follow-up
- About 900 days
- Survival
- Day 918
- Main finding
- Prolonged local disease control with no serious PAE-related complications
- Imaging findings
- Intraprostatic ischemic and cavitary changes on CT, and chronic remodeling on ultrasound
A Frontiers in Veterinary Science case report is putting fresh attention on prostatic artery embolization as a minimally invasive option for canine prostatic carcinoma, this time with unusually long follow-up. The paper tracks a 13-year-old neutered male Chihuahua for roughly 900 days after PAE and reports prolonged local disease control, serial CT and ultrasound changes consistent with sustained ischemic remodeling, and survival to Day 918 without serious procedure-related complications. The authors say this is the longest time-course imaging report published to date for PAE in a dog with prostatic carcinoma. (frontiersin.org)
That matters because canine prostatic carcinoma is still one of the tougher urogenital cancers to manage in practice. Merck Veterinary Manual notes that no curative treatment exists, that metastases are present in more than 80% of dogs at diagnosis, and that total prostatectomy is generally not recommended because of morbidity, including urinary incontinence. Standard management has centered on palliation and multimodal care, including NSAIDs, chemotherapy, radiation therapy, and, in selected centers, interventional approaches. (merckvetmanual.com)
In the new report, the authors designated embolization as Day 0 and followed the dog with CT, ultrasonography, and thoracic radiography. CT identified intraprostatic hypoattenuating lesions by Day 33, with enlargement and gas accumulation by Day 173. Ultrasound later showed hypoechoic lesions by Day 271 that evolved into scattered hyperechoic foci by Day 678, findings the authors interpret as chronic post-ischemic remodeling. They also reported about a 33% reduction in prostatic parenchymal volume, stable through Day 481, while clinical signs remained controlled. (frontiersin.org)
The case also fits into a longer arc of veterinary interventional oncology work rather than arriving out of nowhere. A 2021 JAVMA study previously described the procedure and short-term outcomes of PAE in dogs with prostatic carcinoma, suggesting technical feasibility and early clinical benefit. Separately, a recent review on canine prostate cancer and interventional oncology concluded that long-term data for PAE in dogs remain limited, even though locoregional tumor-volume reduction has been documented. More recently, another report on six dogs with both prostatic carcinoma and bacterial prostatitis suggested PAE can be incorporated into complex case management, but also underscored that progression and metastasis remain major long-term risks. (pubmed.ncbi.nlm.nih.gov)
Industry and academic interest appears to be growing, especially at referral centers with interventional radiology capability. UC Davis has publicly described embolization as its major local disease therapy for prostate cancer in dogs and said many oncologists are considering referral for the procedure as a first-line local therapy. That is not the same as broad standard-of-care adoption, but it does suggest a shift in how some specialty centers are thinking about local control in a disease where conventional options are often limited. (synergy.vetmed.ucdavis.edu)
Why it matters: For veterinary professionals, the practical takeaway is less about cure and more about patient selection, symptom control, and care pathways. This report strengthens the argument that PAE may offer durable local palliation with relatively low immediate procedural morbidity in selected dogs, particularly when obstruction, dysuria, tenesmus, or local mass effect are driving quality-of-life concerns. It may be especially relevant for pet parents seeking alternatives to more invasive surgery or for patients where radiation access, cost, or comorbidity limits options. Still, this remains a single case report, and the wider literature continues to describe canine prostatic carcinoma as an aggressive, commonly metastatic disease. (frontiersin.org)
There are also workflow implications. Because the new paper focuses heavily on serial CT and ultrasound findings, it gives clinicians a more detailed picture of what expected post-PAE remodeling may look like over months to years. That could help with follow-up imaging interpretation, case communication, and distinguishing anticipated treatment effect from progression or secondary complications, although broader validation is still needed. (frontiersin.org)
What to watch: The next step is whether prospective, multi-case studies can define survival benefit, complication rates, ideal embolic protocols, and where PAE fits relative to NSAIDs, radiation therapy, chemotherapy, and combined approaches. Just as important will be access: PAE depends on advanced imaging, interventional radiology expertise, and referral infrastructure, so uptake in general practice will likely hinge on specialty collaboration rather than widespread in-house adoption. (pubmed.ncbi.nlm.nih.gov)